Category: Press Releases
Mavenir Receives the President’s Honor at MSUA’s 2026 Satellite Mobile Innovation Awards
Company honored for outstanding innovation for its AI-driven, cloud-native mobile solutions for terrestrial and non-terrestrial networks WASHINGTON and RICHARDSON, Texas, March 30, 2026 (GLOBE NEWSWIRE) — Mavenir, the software company
How companies are reducing business travel emissions through small digital changes, according to Holafly for Business
DUBLIN, March 30, 2026 (GLOBE NEWSWIRE) — As companies face increasing pressure from investors, regulators and ESG commitments to reduce their carbon footprint, corporate travel is emerging as an area
ROSEN, A LEADING NATIONAL FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LU
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HTGC
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of
ROSEN, A SKILLED INVESTOR RIGHTS LAW FIRM, Encourages Super Micro Computer, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMCI
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between